Wednesday, December 1, 2021

    Latest Posts

    The era of anti-COVID pills begins

    Molnupiravir in Merck works by reducing the ability of the virus to replicate, thereby delaying the disease.

    What if a simple pill helps cure from COVID-19?

    U.S. pharmaceutical giants Merck and Pfizer have announced promising results for oral medications, but also hope that antidepressants could open a new chapter in the fight against pandemics. ..

    What are these treatments?

    These are tablets that are taken orally as soon as the first symptoms of COVID-19 appear, avoiding serious forms of illness and therefore hospitalization.

    This shape process It has been sought after since the beginning of the global health crisis.

    After months of research, Merck and Pfizer say they have reached that elusive goal.

    In early October, Merck said it was seeking approval for Pil-Morne Pil-Bill in the United States, and Pfizer followed on Friday at Pax Rovid.

    Both of these are antiviral agents that act by reducing the ability of the virus to replicate and delaying the disease.

    Both companies say Clinical trial It showed a significant reduction in the risk of hospitalization.

    People who took molnupiravir had a 50% reduction in risk and those who took Paxrovid had a nearly 90% reduction, but direct comparisons of these efficacy rates should be avoided due to different study protocols.

    Fluvoxamine, an antidepressant that is already publicly available, also shows promising results in the prevention of serious forms of COVID-19, according to a study published in October by Brazilian researchers. Lancet Global Health journal.

    Studies show that Pfizer

    Studies have shown that Pfizer’s Paxrovid is 89% effective against serious illness.

    Why are they important?

    Once the effectiveness of these drugs is confirmed, it will be a major step forward in the fight against COVID-19.

    They will add to the vaccine to strengthen the world’s therapeutic weapons against the virus.

    Treatments already exist, mainly in the form of synthetic antibodies.

    However, these drugs are usually intended for people who already have a serious illness, which makes them more difficult to administer because they are injected.

    The pill can be quickly prescribed to the patient and the patient can easily take it at home.

    Merck and Pfizer treatments have not shown many side effects so far, but they require about 10 doses in 5 days.

    “The success of these antivirals could bring a new era to our ability to prevent the serious consequences of SARS-CoV2 infection,” British virologist Stephen Griffin told the Science Media Center.

    What are the restrictions?

    Proper evaluation of Merck and Pfizer treatments has so far been difficult. Both groups only issued statements and did not make clinical trial data available.

    French Infection Expert Carine Lacombe warned in September that these types of presentations should be treated with “caution” until the study is scrutinized.

    She pointed out that these therapies represent a “potentially huge” market for the pharmaceutical group.

    Tablets will add to the vaccine and enhance the world

    Tablets, in addition to vaccines, will enhance the world’s therapeutic weapons against Covid-19.

    Nonetheless, some factors indicate that Merck and Pfizer have not made an empty promise.

    For one thing, the results were extremely strong and an independent oversight committee was okay, so they both discontinued clinical trials earlier than expected.

    When it comes to fluvoxamine, data are available, but not without criticism.

    Some researchers have complained that the author not only evaluated the frequency of hospitalizations, but also the frequency of long-term emergency room stays.

    They say this complicates the interpretation of the data.

    when? And how much is it?

    Merck’s Molnupiravir has already been approved in the United Kingdom. Health authorities On Thursday, they gave their green light for use in patients at risk of developing serious forms of the disease, such as the elderly, obese people, or people suffering from diabetes.

    US and EU health authorities are also urgently considering drugs.

    The European Medicines Agency promised to “accelerate” the process on Thursday without giving a firm date.

    Some countries have already ordered Molnupiravir inventories, such as the United States, and include 1.7 million courses of medication.

    US orders give you a steep price idea drag..

    That’s $ 1.2 billion, which is about $ 700 for a five-day course.

    For Pfizer, we haven’t outlined the pricing of paxlovid, but we promise that it will be “affordable” and will be subject to a gradual pricing approach based on the country’s income level.

    EU Pharmaceutical Agency begins review of Merck’s oral COVID drug

    © 2021 AFP

    Quote: The era of anti-COVID pills begins (November 6, 2021), acquired from on November 6, 2021 I did.

    This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.

    The era of anti-COVID pills begins Source link The era of anti-COVID pills begins

    The post The era of anti-COVID pills begins appeared first on California News Times.

    Latest Posts

    Don't Miss

    Stay in touch

    To be updated with all the latest news, offers and special announcements.